Compare Best Buy Co Inc (BBY) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Best Buy Co Inc vs Enveric Biosciences Inc — how do they compare? Best Buy Co Inc trades at $83.61 (market cap $17.70B), while Enveric Biosciences Inc trades at $1.28 (market cap $5.32M). The key difference: Best Buy Co Inc is far larger — about 3327.1× Enveric Biosciences Inc's market cap, and Best Buy Co Inc pays a 4.57% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| BBY | ENVB | |
|---|---|---|
Market Cap | $17.70B | $5.32M |
Sector | Consumer Cyclical | Health |
52-Week High | $84.00 | $17.40 |
52-Week Low | $55.52 | $1.28 |
Enterprise Value | $20.08B | $408.82K |
Dividend Yield | 4.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Best Buy (BBY) trades at $81.65, down 1.39% on the day, with a bullish technical outlook and strong recent earnings beats. The stock shows robust profitability with a 39.1% ROE and trades at attractive valuations (P/E 15.12, P/S 0.41). Recent news highlights leadership changes and strategic shifts toward higher-margin businesses like marketplace and retail media, supported by new product launches such as RGB LED TVs and Meta VR partnerships.
The outlook is cautiously optimistic with a consensus price target of $82.17 offering modest upside. Key opportunities include dividend yield near 5% and earnings momentum, while risks involve revenue declines, competitive pressures, and macroeconomic sensitivity. Analyst sentiment is mixed with 34% buy ratings, reflecting balanced views on growth potential versus execution challenges.
ENVB trades at $1.33, down 1.48% on the day, with a bearish technical signal from moving averages despite neutral oscillators. The company shows significant financial challenges with negative ROE of -257.95% and ROA of -218.01%, though it has consistently beaten earnings expectations in recent quarters. Recent news highlights active participation in investor conferences and progress with EB-003 drug candidate development.
While analyst consensus is 75% buy-rated, the stock faces substantial fundamental risks from negative profitability and cash burn. Investment opportunity exists if clinical developments succeed, but shareholders should weigh high operational losses against potential biotech breakthroughs in the neuroplastogenic therapeutics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Best Buy Co Inc
With $51.8 billion in fiscal 2022 sales, Best Buy is the largest pure-play consumer electronics retailer in the U.S., with roughly 10.6% share of the aggregate market and north of 40% share of offline sales, per our calculations, CTA industry, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the COVID-19 pandemic, have seen the U.S. e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.
Read more on BBY →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
